Reglagene's lead product, RGN6024, was accepted into TMC's Accelerator for Cancer Therapeutics. Find the full announcement below or on the EIN Presswire.

Reglagene's lead product, RGN6024, has received an exclusive orphan drug designation from the FDA. Read the full announcement here, or on the EIN Presswire.

We’re proud to share the news that Reglagene has completed a $5.4M private placement of its convertible preferred stock. With the support of our investors and partners, we’re well equipped to take the next steps in the development of our orally administered therapy, RGN6024. Read the full press release below or on the EIN PressWire.

This step confirms the safety and pharmacological activity exhibited by a drug for commercial development and paves the way to the next step: the initiation of human clinical trials.